Author | Benjamin P. Saylor


Microhematuria guideline emphasizes risk-stratified approach

July 31, 2020


A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.

FDA approves additional recommended dosage for anti-PD-1 therapy

May 13, 2020


The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.

Dr. Thrasher discusses COVID-19's impact on the ABU, telemedicine, research

April 28, 2020


J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.

Dr. Rosevear: Practicing in a pandemic

April 22, 2020


Henry Rosevear, MD, talks about how he and his practice are coping with the COVID-19 pandemic.